肝细胞癌防治热点与策略

杨永平

肝细胞癌防治热点与策略

杨永平

中国人民解放军第302医院肝脏肿瘤诊疗与研究中心

基金项目:

全军“十二五”科研重点项目(BWS11J074)；首都医学发展基金课题(2009-2041)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2433
- HTML全文浏览量: 14
- PDF下载量: 822
- 被引次数: 0
出版历程
- 出版日期: 2013-01-20

Current perspectives in preventive and therapeutic strategies for hepatocellular carcinoma

Yang YongPing

Research funding:

摘要

摘要:
对肝细胞癌(HCC)的防治已成为人类一大挑战。近年来,在HCC的临床和基础肿瘤细胞生物学研究方面均有较大进展,出现了一批可提供高级别循证医学证据的临床试验结果,也为HCC的防治带来新的关注热点。临床实践中仍然存在不规范治疗和费效比低等严重问题。本文论及HCC防治的热点,旨在指导医生遵守循证医学证据,采用个体化、优化治疗策略,使HCC患者临床治疗最大获益。
- 癌 /
- 肝细胞
Abstract:
Prevention and clinical management of hepatocellular carcinoma (HCC) remains a significant challenge.In recent years, extensive research efforts have been put forth to determine the cytobiological characteristics of HCC and their clinical relevance, with the aim of developing more effective preventive and therapeutic strategies.Currently, a wide range of treatment modalities is available, but these are characterized as having low cost-effective ratios.While the ultimate goal is to create and implement an effective preventive strategy so that onset of HCC is completely eradicated, until that time improved clinical management of the available treatment modalities is the most promising option for promoting patient quality of life and survival.The purpose of this document is to assist physicians in the treatment decision-making process by relying on evidence-based data to choose the most appropriate strategies for individual patients.
- carcinoma /
- hepatocellular

HTML全文

参考文献(37)

[1] Parkin DM, Bray F, Ferlay J, et al.Global cancer statistics, 2002[J].CA Cancer J Clin, 2005, 55 (2) :74-108.

[2]Yuen MF, Hou JL, Chutaputti A.Hepatocellular carcinoma inthe Asian pacific region[J].J Gastroenterol Hepatol, 2009, 24 (3) :346-353.

[3]Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al.Virological suppression does not prevent the development ofhepatocellular carcinoma in HBeAg-negative chronic hepati-tis B patients with cirrhosis receiving oral antiviral (s) startingwith lamivudine monotherapy:results of the nationwideHEPNET.Greece cohort study[J].Gut, 2011, 60 (8) :1109-1116.

[4]Venook AP, Papandreou C, Furuse J, et al.The incidenceand epidemiology of hepatocellular carcinoma:a global andregional perspective[J].Oncologist, 2010, 15 (Suppl 4) :S5-S13.

[5]Yang JD, Roberts LR.Hepatocellular carcinoma:A global view[J].Nat Rev Gastroenterol Hepatol, 2010, 7 (8) :448-458.

[6]El-Serag HB.Epidemiology of hepatocellular carcinoma inUSA[J].Hepatol Res, 2007, 37 (Suppl 2) :S88-S94.

[7]Chang MH, Chen CJ, Lai MS, et al.Universal hepatitis Bvaccination in Taiwan and the incidence of hepatocellular car-cinoma in children.Taiwan Childhood Hepatoma Study Group[J].N Engl J Med, 1997, 336 (26) :1855-1859.

[8]Yuen MF, Hou JL, Chutaputti A.Hepatocellular carcinoma inthe Asian Pacific region.[J]Gastroenterol Hepatol, 2009, 24 (3) :346-353.

[9] Di Marco V, Lo Iacono O, CammàC, et al.The long-termcourse of chronic hepatitis B[J].Hepatology, 1999, 30 (1) :257-264.

[10]Singal AG, Volk ML, Jensen D, et al.A sustained viral re-sponse is associated with reduced liver-related morbidityand mortality in patients with hepatitis C virus[J].Clin Gas-troenterol Hepatol, 2010, 8 (3) :280-288.

[11]Marrero J, Fontana R, Fu S, et al.Alcohol, tobacco and o-besity are synergistic risk factors for hepatocellular carcinoma[J].J Hepatol, 2005, 42 (2) :218-224.

[12]Tanabe KK, Lemoine A, Finkelstein DM, et al.Epidermal growthfactor gene functional polymorphism and the risk of hepatocellularcarcinoma in patients with cirrhosis[J].JAMA, 2008, 299 (1) :53-60.

[13]Poon RT, Fan ST, Ng IO, et al.Different risk factors and prog-nosis for early and late intrahepatic recurrence after resection ofhepatocellular carcinoma[J].Cancer, 2000, 89 (3) :500-507.

[14]Llovet JM, Schwartz M, Mazzaferro V.Resection and livertransplantation for hepatocellular carcinoma[J].Semin LiverDis, 2005, 25 (2) :181-200.

[15]芮静安, 刘振文.原发性肝癌外科治疗的理性思考[J].传染病信息, 2009, 22 (2) :69-72.

[16]陆荫英, 陈艳, 冯永毅.肝癌冷冻治疗的临床研究进展[J].传染病信息, 2009, 22 (2) :123-126.

[17]Lu DS, Yu NC, Raman SS, et al.Percutaneous radiofrequencyablation of hepatocellular carcinoma as a bridge to liver trans-plantation[J].Hepatology, 2005, 41 (5) :1130-1137.

[18]Gish RG, Porta C, Lazar L, et al.Phase III randomized con-trolled trial comparing the survival of patients with unresect-able hepatocellular carcinoma treated with nolatrexed ordoxorubicin[J].J Clin Oncol, 2007, 25 (21) :3069-3075.

[19]Yeo W, Mok TS, Zee B, et al.A randomized phase III studyof doxorubicin versus cisplatin/interferon alpha-2b/doxoru-bicin/fluorouracil (PIAF) combination chemotherapy for unr-esectable hepatocellular carcinoma[J].J Natl Cancer Inst, 2005, 97 (20) :1532-1538.

[20]Edeline J, Raoul JL, Vauleon E, et al.Systemic chemother-apy for hepatocellular carcinoma in non-cirrhotic liver:a ret-rospective study[J].World J Gastroenterol, 2009, 15 (6) :713-716.

[21]Barbare JC, BouchéO, Bonnetain F, et al.Randomized controlledtrial of tamoxifen in advanced hepatocellular carcinoma[J].J ClinOncol, 2005, 23 (19) :4338-4346.

[22]Nowak A, Findlay M, Culjak G, et al.Tamoxifen for hepato-cellular carcinoma[J].Cochrane Database Syst Rev, 2004, (3) :CD001024.

[23]Mazzaferro V, Romito R, Schiavo M, et al.Prevention of hepa-tocellular carcinoma recurrence with alpha-interferon after liverresection in HCV cirrhosis[J].Hepatology, 2006, 44 (6) :1543-1554.

[24]Qin S, Bai Y, Ye S, et al.Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin aspalliative systemic chemotherapy in advanced HCC in Asianpatients[J].J Clin Oncol, 2010, 28 (Suppl) :S15.

[25]Avila MA, Berasain C, Sangro B, et al.New therapies forhepatocellular carcinoma[J].Oncogene, 2006, 25 (27) :3866-3884.

[26]Greten TF, Korangy F, Manns MP, et al.Molecular therapyfor the treatment of hepatocellular carcinoma[J].Br J Canc-er, 2009, 100 (1) :19-23.

[27]Cook KM, Figg WD.Angiogenesis inhibitors:current strate-gies and future prospects[J].CA Cancer J Clin, 2010, 60 (4) :222-243.

[28] Slamon DJ, Leyland-Jones B, Shak S, et al.Use of chem-otherapy plus a monoclonal antibody against HER2 for meta-static breast cancer that overexpresses HER2[J].N Engl JMed, 2001, 344 (11) :783-792.

[29] Tsao MS, Sakurada A, Cutz JC, et al.Erlotinib in lung canc-er-molecular and clinical predictors of outcome[J].N EnglJ Med, 2005, 353 (2) :133-144.

[30]Flaherty KT, Puzanov I, Kim KB, et al.Inhibition of mutated, activated BRAF in metastatic melanoma[J].N Engl J Med, 2010, 363 (23) :809-819.

[31]Yau T, Chan P, Epstein R, et al.Management of advancedhepatocellular carcinoma in era of targed therapy[J].LiverInternational, 2009, 29 (1) :10-17.

[32]Witjes CD, Verhoef C, Verheul HM, et al.Syetemic treat-ment in hepatocellular carcinoma;“a small step for man…”[J].Neth J Med, 2009, 67 (3) :86-90.

[33]Lencioni R, Marrero J, Venook A, et al.Design and rationalefor the non-interventional Global Investigation of therapeuticDEcisions in hepatocellular carcinoma and of its treatmentwith sorafeNib (GIDEON) study[J].Int J Clin Pract, 2010, 64 (8) :1034-1041.

[34] Yang Y, Lu Y, Wang C, et al.Cryotherapy is associated withimproved clinical outcomes of sorafenib therapy for advancedhepatocellular carcinoma[J].Cell Biochemistry Biophys, 2012, 63 (2) :159-169.

[35]Bruix J, Llovet JM.Major achievements in hepatocellular carci-noma[J].Lancet, 2009, 373 (9664) :614-616.

[36]栗光明, 冷希圣.肝癌及其治疗[J].传染病信息, 2009, 22 (2) :115-118.

[37]Hornberg JJ, Bruggeman FJ, Westerhoff HV, et al.Cancer:a Systems Biology disease[J].Biosystems, 2006, 83 (2-3) :81-90.

施引文献

资源附件(0)

访问统计